Teicoplanin

Overview

Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.

Indication

For the treatment of bacterial infections caused by susceptible microorganisms.

Associated Conditions

Angina Pectoris
Anginal Pain
Bacteremia
Bloodstream Infections (BSI)
Bone and Joint Infections
Clostridium Difficile
Clostridium Difficile Infection (CDI)
Community Acquired Pneumonia (CAP)
Complicated Urinary Tract Infection
Infective Endocarditis (IE)
Lower Respiratory Tract and Lung Infections
Non-complicated Skin and Soft Tissue Infections
Nosocomial Pneumonia
Peritonitis
Skin and Soft Tissue Infections (SSTIs)
Urinary Tract Infection

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.	2025/02/10	NCT06818565	Not Applicable	Not yet recruiting	Institute of Liver and Biliary Sciences, India
TDM-optimized Teicoplanin Dosing Versus Standard of Care	2023/06/22	NCT05914467	Phase 4	Recruiting	Radboud University Medical Center
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy	2020/04/30	NCT04370145	Phase 4	Completed	Tongji Hospital
Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection	2020/04/10	NCT04341831	Phase 3	UNKNOWN	Bezmialem Vakif University
Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients	2019/11/25	NCT04176328	Phase 1	Completed	Neupharma Srl
Efficacy and Safety of Teicoplanin in CDAD	2019/07/01	NCT04003818	Phase 4	Terminated	Sanofi
the Clinical Trial of Teicoplanin for Injection	2017/01/13	NCT03020901	N/A	UNKNOWN	Jiangsu Famous Medical Technology Co., Ltd.
PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4	2016/01/11	NCT02652169	Not Applicable	Recruiting	Medical University of Vienna
The Amputation Surgical Site Infection Trial (ASSIT)	2013/12/23	NCT02018094	Phase 4	Completed	Hull University Teaching Hospitals NHS Trust
Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study	2013/03/21	NCT01815541	Phase 2	Completed	Centre Hospitalier Universitaire, Amiens

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
TEICOPLANIN MEDSURGE teicoplanin 400mg powder for injection vial with diluent ampoule	389258	Medsurge Pharma Pty Ltd	Medicine	A	6/28/2023
TARGOCID teicoplanin 400mg injection	47886	Sanofi-Aventis Australia Pty Ltd	Medicine	A	2/22/1994
TEICOPLANIN SANDOZ teicoplanin 400mg powder for injection vial with diluent ampoule	157812	Sandoz Pty Ltd	Medicine	A	8/11/2010
TEICOPLANIN SXP teicoplanin 400 mg powder for injection with diluent ampoule	259192	Southern Cross Pharma Pty Ltd	Medicine	A	6/7/2017
TEICOPLANIN MEDICIANZ teicoplanin 400mg powder for injection vial with diluent ampoule	389256	Medsurge Pharma Pty Ltd	Medicine	A	6/28/2023

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
TEICOPLANINA SALA 400 MG POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Laboratorio Reig Jofre, S.A.	78751	POLVO PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Commercialized
TEICOPLANINA ALTAN 200 MG POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Altan Pharmaceuticals Sa	83080	POLVO PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Commercialized
TEICOPLANINA ACCORD 400 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Accord Healthcare S.L.U.	78614	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized
TEICOPLANINA ACCORDPHARMA 200 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Accord Healthcare S.L.U.	78341	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE	Uso Hospitalario	Not Commercialized
TEICOPLANINA NORIDEM 200 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Noridem Enterprises Limited	80097	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE	Uso Hospitalario	Commercialized
TARGOCID 200 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION	Sanofi Aventis S.A.	58921	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized
TEICOPLANINA ALTAN 400 MG POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Altan Pharmaceuticals Sa	83081	POLVO PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Commercialized
TARGOCID 400 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION	Sanofi Aventis S.A.	58922	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Commercialized
TEICOPLANINA NORIDEM 400 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Noridem Enterprises Limited	80096	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE	Uso Hospitalario	Commercialized
TEICOPLANINA ACCORD 200 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG	Accord Healthcare S.L.U.	78613	POLVO Y DISOLVENTE PARA SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access